Background
==========

Identifying genes for variation in the range of normal intelligence could provide important clues to the genetic etiology of disturbed cognition in e.g. autism, reading disorder, and ADHD. Since the earliest 90\'s several groups have focussed on the identification -- and subsequent replication -- of common genetic polymorphisms underlying normal variation in cognitive abilities \[[@B1]-[@B5]\]. Among a handful of candidate genes that have been investigated in relation to normal cognitive variation as summarized in Posthuma & De Geus 2006 \[[@B6]\], the muscarinic 2 cholinergic receptor gene (*CHRM2*) has been consistently found to be associated with cognitive ability, and currently is the best replicated gene associated with general intelligence. A population-based association study conducted by Comings *et al*. (2003) \[[@B7]\] reported an association between a 3\'UTR variant of the cholinergic muscarinic receptor 2 (*CHRM2*) gene explaining 1% of the variance in scores on full-scale IQ (FSIQ), and years of education. Suggestive evidence for linkage with performance IQ was found at 7q31-36, in the vicinity of the *CHRM2*gene in a genome scan for intelligence based on 329 Australian families and 100 Dutch families, totalling 625 sib-pairs \[[@B4]\]. We subsequently reported association between genetic variants within the *CHRM2*gene and intelligence quotient (IQ) using two independent Dutch cohorts \[[@B8]\]. This finding was then replicated by Dick and colleagues \[[@B9]\]. All three association studies (Comings *et al*., 2003; Gosso *et al*., 2006; Dick *et al*., 2007) report significant association with IQ and non coding regions within in the *CHRM2*gene (rs81919992 located in the 3\' untranslated region (UTR) \[[@B7]\], and rs2061174 \[[@B9]\], and rs324650 \[[@B8]\] in introns 4 and 5, respectively).

The *CHRM2*gene belongs to the superfamily of G-protein-coupled receptors (GPCRs). Muscarinic acetylcholine receptors (M~1~-M~5~) activate a multitude of signaling pathways important for modulating neuronal excitability, synaptic plasticity and feedback regulation of acetylcholine (ACh) release \[[@B10],[@B11]\]. Combined behavioral and pharmacological animal studies involving M~2~antagonists have shown the importance of cholinergic receptor activity for acquisition and retrieval of several learning tasks \[[@B12]-[@B16]\].

Despite its confirmed putative role in cognitive processes, further evidence for genetic regulatory variants on the *CHRM2*gene have been difficult to assess, mainly due to its complex transcriptional expression patterns. Three different *CHRM2*promoters have been reported based on work performed on different human cell lines \[[@B17]\]. In combination with *alternative*splicing patterns this results in, at least, 6 different mRNA transcripts encoding for the same receptor protein (isoforms A till F)\[[@B17],[@B18]\]. Promoter activity for the *CHRM2*gene was postulated to be tissue specific. The first promoter located upstream of exon 1, was preferentially used in cardiac cells (isoforms A and B); promoter 2 on intron 1 alternatively expressed on brain (isoforms C and D); and a third promoter located on intro 2 non-tissue specific (isoforms E and F). Independently, Zhou and coworkers \[[@B19]\] reported a fourth putative promoter region on intron 5, but this last result has not been independently confirmed yet \[[@B17]\]. Although *CHRM2*promoter usage is believed to be tissue specific, a single protein receptor is encoded. The functional significance of these transcripts is still unknown.

To fine-map the *CHRM2*gene and to detect its functional role in cognitive ability, we genotyped a dense set of *tag*-SNPs within and flanking the *CHRM2*gene in a sample of 762 Dutch individuals from 358 twin families belonging to two different age cohorts (mean ages 12.4 and 37.6). A family based genetic association test was used, which allows evaluating evidence for association free from spurious effects of population stratification \[[@B20]-[@B22]\]. In addition, gene expression assays were performed on brain controls to determine whether a significant correlation exists between the associated SNPs and CHRM2 gene expression levels.

Methods
=======

Subjects
--------

All young and adult twins and their siblings were part of two larger cognitive studies and were recruited from the Netherlands Twin Registry \[[@B23],[@B24]\]. We have shown previously that the adult participants are representative of the Dutch population with respect to intelligence \[[@B25]\]. Informed consent was obtained from the participants (adult cohort) or from their parents if they were under 18 (young cohort). The study was approved by the institutional review board of the VU University Medical Center. None of the individuals tested suffered from severe physical or mental handicaps, as assessed through surveys sent out to participants or their parents every two years.

Young Cohort
------------

The young cohort consisted of 177 twin pairs born between 1990 and 1992, and 55 siblings \[[@B6],[@B26]\], of which 371 were available for genotyping. Mean age of the genotyped twins was 12.4 (SD = 0.9) years of age and the siblings were between 8 and 15 years old at the time of testing. There were 35 monozygotic male twin pairs (MZM), 28 dizygotic male twin pairs (DZM), 48 monozygotic female twin pairs (MZF), 23 dizygotic female twin pairs (DZF), 26 dizygotic opposite-sex twin pairs (DOS), 24 male siblings and 24 female siblings, and 3 subjects form incomplete twin pairs (1 male, 2 females). Participation in this study included a voluntary agreement to provide buccal swabs for DNA extraction.

This sample is similar to the sample used in our initial analyses, except for twenty individuals that were deleted from analyses in the current sample due to additional genotyping and a more stringent threshold of genotyping failure per individual.

Adult Cohort
------------

A total of 793 family members from 317 extended twin families participated in the adult cognition study \[[@B4]\]. Participation in this study did not automatically include DNA collection, however, part of the sample (276 subjects) returned to the lab to provide blood samples. The sample characteristics have been described elsewhere \[[@B27]\]. One hundred fifteen additional individuals provided buccal swabs via our biobanking project \[[@B28]\] for DNA extraction. Mean age of the total genotyped sample was 36.2 years (SD = 12.6). There were 25 monozygotic male twin pairs (MZM), 15 dizygotic male twin pairs (DZM), 1 DZM triplet, 20 monozygotic female twin pairs (MZF), 28 dizygotic female twin pairs (DZF) and 23 dizygotic opposite-sex twin pairs (DOS), 29 female siblings and 28 male siblings, and 109 subjects from incomplete twin pairs (41 males, 68 females).

Cognitive testing
-----------------

In the young cohort, cognitive ability was assessed with the Dutch adaptation of the WISC-R \[[@B29]\], and consisted of four verbal subtests (similarities, vocabulary, arithmetic, and digit span) and two performance subtests (block design, and object assembly).

In the adult cohort, the Dutch adaptation of the WAISIII-R \[[@B30]\], assessed IQ and consisted of four verbal subtests (VIQ: information, similarities, vocabulary, and arithmetic) and four performance subtests (PIQ: picture completion, block design, matrix reasoning, and digit-symbol substitution). The correlation between verbal IQ and performance IQ is usually around 0.50 (0.53 in our data), implying that only 25% of the variance in PIQ and VIQ is shared. Thus, a substantial part of the variance in these two measures is non-overlapping, and theoretically they are expected to capture different aspects of cognitive ability. We therefore included VIQ and PIQ as measures of the two different aspects of intelligence as well as Full scale IQ (FSIQ) as a general measure of intelligence. In both cohorts, VIQ, PIQ and FSIQ were normally distributed, (see Table [1](#T1){ref-type="table"}).

###### 

Means and standard deviations of IQ (corrected for age and sex effects) in the Young and Adult cohorts

                 *Young Cohort*   *Adult Cohort*                                                                                                       
  -------------- ---------------- --------------------- ---------------- --------------------- ---------------- --------------------- ---------------- ---------------------
                 *Total sample*   *Skewness Kurtosis*   *Genotyped*      *Skewness Kurtosis*   *Total sample*   *Skewness Kurtosis*   *Genotyped*      *Skewness Kurtosis*
                                                                                                                                                       
  N              407                                    371                                    793                                    391              
  Gender (M/F)   191/216                                176/195                                348/445                                175/216          
  Age (SD)       12.37 (0.93)                           12.37 (0.92)                           37.60 (13.00)                          36.25 (12.64)    
  PIQ (SD)       94.57 (18.93)    0.165/-0.308          94.85 (19.14)    0.175/-0.304          104.49 (12.34)   0.197/0.099           104.30 (11.64)   0.135/0.312
  VIQ(SD)        102.56 (12.74)   0.121/0.242           102.64 (12.92)   -0.080/-0.332         103.69 (12.26)   -0.308/-0.005         104.23 (12.15)   -0.410/0.256
  FSIQ (SD)      98.65 (15.06)    -0.042/-0.252         98.84 (15.24)    -0.037/-0.254         103.56 (11.49)   0.087/0.167           103.81 (11.16)   0.073/0.512

For both cohorts IQ scores standardized for the effects of age and sex were calculated. These were then z-transformed within cohorts to allow easy comparison across cohorts and across different tests.

DNA collection and isolation
----------------------------

Buccal swabs were collected from 371 children; DNA in adults was collected from blood samples in 391 adults. The DNA isolation from buccal swabs was performed using a cloroform/isopropanol extraction \[[@B31],[@B32]\]. DNA was extracted from blood samples using the salting out protocol described elsewhere \[[@B33]\]. Zygosity was assessed using 11 highly polymorphic microsatellite markers (Heterozygosity \> 0.80). Genotyping was performed blind to familial status and phenotypic data.

DNA and RNA extraction from tissue homogenates
----------------------------------------------

Control brains from 50 individuals, 23 males with a mean age of 70.3 years (SD = 9.38), and 27 females with a mean age of 73.3 years (SD = 10.50) were obtained at autopsy from *The Netherlands Brain Bank*(NBB) \[[@B34]\]. This material comes mainly from the superior and inferior parietal lobe. DNA isolation from 0.20 gram of frozen tissue was performed using the Puregene™ Kit (Gentra Systems, USA) according to standard protocol and doubled volume of all reagents per tissue weight. To verify DNA isolation, products were run on a 1% agarose gel.

Total RNA was isolated from 0.10 gram of frozen brain tissue with RNA-Bee™ following the manufacturer\'s recommendations (Isotex Diagnostics, Inc., USA). RNA was purified using the Qiagen RNeasy Mini kit (Qiagen Benelux B.V., The Netherlands) and verified on a 2% agarose gel. Five μg RNA was used to make cDNA using 200 U of Superscript™ III Reverse Transcriptase (Invitrogen, The Netherlands) in First Strand Buffer (Invitrogen, The Netherlands), 3.4 \* 10^-2^μg/μl random hexamer oligo, 3.4 \* 10^-2^μg/μl poly d(T) 12--18, 1.3 mM dNTPs, 1.1 μM DTT (Invitrogen, The Netherlands), 10 U RNaseOUT™ Ribonuclease Inhibitor Recombinant (Invitrogen, The Netherlands) and incubated two hours at 50°C. Subsequently, 20 U RNase H (Invitrogen, The Netherlands) was added and incubated 30 minutes at 37°C. Products were run on a 1% agarose gel to examine the quality.

Genotyping
----------

Single nucleotide polymorphisms (SNPs) were selected using the information available from the International HapMap Project. SNP selection was based on a randomly selected population with northern and western European ancestry by the Centre d\'Etude du polymorphisme Humain (CEPH) \[[@B35]\]. The Minor Allele Frequency MAF had to be \> 0.05 in order to exclude rare homozygous genotypes. Forty-two SNPs within the *CHRM2*gene were thus selected from the CEPH population using Haploview version 3.32 (NCBI build 36.1).

SNP genotyping was performed using the SNPlex^®^assay platform. The SNPlex assay was conducted following the manufacturer\'s recommendations (Applied Biosystems, Foster city, CA, USA). All pre-PCR steps were performed on a cooled block. Reactions were carried out in Gene Amp 9700 Thermocycler (Applied Biosystems, Foster city, CA, USA). Data was analyzed using Genemapper v3.7 (Applied Biosystems, Foster city, CA, USA).

CHRM2 transcripts at brain level
--------------------------------

Three different primer combinations were used to investigate the presence of CHRM2 transcript variants in normal brain controls. Forward primers F~A&B~GAGGCATCCAGGTCTCCAT, F~C&D~CGCAGCTCTCGCCA-GAGCCTT, and F~E&F~AAAGGACTCCTCGCTCCTTC were used in combination with a unique reverse primer R~A-F~CCCGATAATGGTCACCAAAC in order to tag isoforms A till F. PCR was performed at 94°C for 30 sec, 55°C for 30 sec, and 72°C for 1:30 min, for 40 cycles, followed by a 7 min extension at 72°C. To verify primers specificity PCR products were run on a 2% agarose gel.

Gene expression assay
---------------------

RT-PCR was performed using specific primers encompassing the untranslated exon 5 (the last untranslated exon), which is present in all mRNA transcripts, and the coding sequence (CDS) of the *CHRM2*gene; F-GAAACCAGCGACAGGTTTAAATG, R-GCTATTGTTAGAGGA-GTTTGTTGAGTTATTC. PCR was carried out at 94°C for 1 min, 64°C for 1 min, and 72°C for 1 min, for 40 cycles, followed by a 10 min extension at 72°C. Optimization of primer concentration and cDNA input was performed and dissociation curves for the selected primers obtained. Two housekeeping genes -- *β-actin*and *HPRT*-- were used as internal controls. RT-PCR reactions were performed twice independently, each time in duplicate.

Statistical analyses
--------------------

Allele frequencies of all SNPs were estimated in both the children and adult cohorts using Haploview \[[@B36]\] in which a Hardy-Weinberg test is implemented, based on an exact calculation of the probability of observing a certain number of heterozygotes conditional on the number of copies of the minor SNP allele.

Genetic association tests were conducted using the program QTDT which implements the orthogonal model proposed by Abecasis *et al*., 2000 \[[@B20]\] (see also Fulker *et al*., 1999; Posthuma *et al*., 2004 \[[@B21],[@B22]\]). This model allows one to decompose the genotypic effect into orthogonal between- (β~b~) and within- (β~w~) family components, and also models the residual sib-correlation as a function of polygenic or environmental factors. MZ twins can be included and are modelled as such, by adding zygosity status to the datafile. They are not informative to the within family component (unless they are paired with non-twin siblings), but are informative for the between family component. The between-family association component is sensitive to population admixture, whereas the within-family component is significant only in the presence of LD due to close linkage. The models used in QTDT take into account additive allelic between- and within family effects.

It is worth noting that, if population stratification acts to create a false association, the test for association using the within family component is still valid. More importantly, if population stratification acts to hide a genuine association, the test for association using the within family component has more power to detect this association than a population based association test. A significance level α of 0.01 was chosen.

Results
=======

Genotyping success rate was 95.36 (SD = 3.80) among both cohorts. Six *tag-*SNPs, (rs6957496, rs1424569, rs10488600, rs17494540, rs324582, and rs11773032), although with high genotyping rate, deviated from HWE (*P \< 0.05*) despite a high genotype call rate. One *tag-*SNP, rs11773032 showed no variation in our population and was thus deleted from further analysis. LD parameters D\' and r^2^were obtained for all successfully genotyped SNPs. LD blocks were generated applying the algorithm defined by Gabriel *et al*., 2002 \[[@B37]\] in which confidence bounds on D\' are generated if 95% of the information shows \"strong LD\". By default, this method ignores markers with MAF \< 0.05 (see Figure [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}).

![Location of single nucleotide polymorphisms (SNPs) within the *CHRM2*gene on chromosome 7 and LD blocks defined by them, respectively. Coding sequence (CDS) is depicted in black. Untranslated exons (Exon 1 till Exon 5) are depicted in grey. SNPs already reported in our previous study (Gosso *et al*., 2006) are in **bold.**](1471-2350-8-66-1){#F1}

###### 

SNPs descriptives for *young*, *adult*and *combined*cohorts

                    rs\#             Position^a^   *Tagged SNP*     LD~BLOCK~    MA   MAF Young   MAF Adult   HWE-pval   %Geno
  ---- ------------ ---------------- ------------- ---------------- ------------ ---- ----------- ----------- ---------- -------
  1    *5\'UTR*     rs7797223        136198443                                   T    0.25        0.26        0.77       95.6
  2                 **rs6957496**    136202377     1                             G    0.09        0.11        0.02       96.6
                                                                                                                         
  3    *intron 3*   **rs12533282**   136207518     1, 4, 5,         1(1 kb)      G    0.18        0.17        0.40       98.6
  4                 rs10488595       136208970                                   A    0.18        0.17        0.71       97.7
  5                 rs10488596       136209134                                   T    0.18        0.16        0.37       97.2
  6                 **rs1424569**    136211219                                   A    0.44        0.47        0.02       94.8
  7                 **rs17415326**   136214872                                   C    0.02        0.05        0.48       95.1
  8                 rs1424548        136219956                                   T    0.37        0.36        0.53       98.2
  9                 **rs4475425**    136225739                      2 (5 Kb)     A    0.21        0.24        0.87       94.8
  10                **rs1364405**    136231025     41                            A    0.35        0.33        0.08       97.9
  11                **rs1364402**    136234903                      3 (17 kb)    C    0.12        0.11        1.00       98.7
  12                **rs2350780**    136243509                                   G    0.40        0.39        0.59       98.8
  13                **rs7810473**    136246997                                   G    0.42        0.42        0.30       98.9
  14                rs1364404        136248827                                   T    0.31        0.32        0.62       98.1
  15                **rs1469179**    136251497     22                            A    0.44        0.46        0.18       97.3
  16                rs17496259       136251883                                   A    0.31        0.31        0.48       95.8
  17                rs17411478       136251909                                   T    0.31        0.32        0.37       99.1
  18                **rs10488600**   136255998                                   T    0.10        0.13        0.00       98.0
  19                **rs17494589**   136256129     26                            A    0.20        0.18        0.07       94.9
  20                **rs17168817**   136258808                                   T    0.08        0.06        0.87       99.2
  21                rs1364409        136262573                      4 (12 kb)    T    0.32        0.35        0.13       96.4
  22                rs6947206        136265651                                   C    0.46        0.48        0.12       94.0
  23                **rs7782965**    136274673     21, 26, 27                    T    0.32        0.35        0.45       90.4
  24                rs17494540       136277380                                   C    0.20        0.18        0.01       96.3
  25                rs1424387        136282543                                   C    0.31        0.31        0.39       99.0
  26                rs1378646        136285541                      5 (2 kb)     G    0.35        0.37        0.32       98.8
                                                                                                                         
  27   *intron 4*   rs1158586        136287676                                   G    0.34        0.40        0.42       93.0
  28                **rs324582**     136301147                                   G    0.07        0.10        0.02       96.4
  29                **rs2061174**    136311940     30               6 (10 kb)    G    0.34        0.35        0.93       84.6
  30                rs7799047        136322098                                   G    0.34        0.35        1.00       93.5
                                                                                                                         
  31   *intron 5*   **rs17411561**   136332728     14, 16, 17, 25                C    0.32        0.25        0.25       87.7
  32                rs420817         136337943                      7 (11 kb)    C    0.48        0.47        0.21       95.7
  33                **rs324640**     136339536     32                            G    0.46        0.50        0.17       86.2
  34                **rs10488602**   136341043                                   C    0.22        0.23        0.43       98.1
  35                rs324647         136343292                                   C    0.14        0.15        0.13       95.9
  36                **rs324650**     136344201                                   T    0.47        0.48        0.08       85.2
  37                **rs324651**     136349801     35                            T    0.14        0.14        0.13       93.1
                                                                                                                         
  38   *3\'UTR*     **rs8191992**    136351848                      8 (0.2 kb)   T    0.45        0.48        0.60       96.5
  39                **rs8191993**    136352103                                   G    0.35        0.35        0.93       94.9
  40                **rs7780181**    136357075                                   G    0.42        0.44        0.83       98.7
  41                rs1424543        136360300                                   C    0.36        0.32        0.01       95.4
  42                **rs11971309**   136362695     8                             T    0.38        0.37        0.57       90.0
  43                **rs11773032**   136391582                                   A    0.00        0.01        1.00       98.1

^a^Chromosomal single nucleotide position (SNP) position based on *Build 36.1*. *Tag-*SNPs are depicted in **bold**. *Abbreviations*: LD, Linkage disequilibrium; MA, Minor Allele, MAF Minor Allele Frequency; HWE, Hardy-Weinberg Equilibrium

Two 5\'UTR SNPs, previously reported, showed the strongest association with IQ, rs2061174 (intron 4) in the *adult*cohort and rs324650 (intron 5) in the *young*cohort \[[@B8]\] (see Figure [2](#F2){ref-type="fig"}). Within-family genetic effects were reflected in an increased IQ of 6.89 (PIQ) points for those individuals carrying the \"A\" allele of rs2061174 within the *adult*cohort. individuals in the *young*cohort bearing the \"T\" allele of rs324650 showed an increment of 5.30 IQ (VIQ) points (see Tables [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}). Interestingly, the most significant variant in the *young*cohort, rs324650, is part of a short interspersed repeat (SINE), namely a MIRb (mammalian-wide interspersed repeat) repeat of 160 bp long. The derived \"T\" allele contained in this repeat seems to be human-specific. In addition this MIRb repeat is also present in non-human primate linages -- rhesus (*macaca mulatta*) and chimpanzee (*pan troglodytes*) -- but not in other mammalian linages. Such an allele-specific effect may reflect that the variant is in LD with the *causal*allele, or that the \"T\" allele is directly modifying binding-properties of transcription starting sites (TSS) \[[@B38]\].

![QTDT family-based results for *tag-SNPs*plotted against FSIQ, VIQ, and PIQ for *young*(A) and *adult*(B)cohorts.](1471-2350-8-66-2){#F2}

###### 

Means (SD) per genotype for PIQ, VIQ and FIQ for *young*and *adult*cohorts for the most significant SNPs within the *CHRM2*gene

  **SNP**             **Young Cohort**                    **Adult Cohort**                                                            
  ------------- ----- ------------------ ---------------- ------------------ ----- ---------------- ---------------- ---------------- -----
                      **AA**             **AG**           **GG**                   **AA**           **AG**           **GG**           
                      *0.38*             *0.46*           *0.17*                   *0.39*           *0.47*           *0.14*           
  rs2350780     PIQ   94.43 (18.96)      95.21 (19.86)    95.94 (17.59)      366   104.77 (12.93)   104.61 (11.44)   104.37 (10.81)   359
  (136243509)   VIQ   102.24 (13.67)     103.07 (12.69)   104.17 (11.67)     367   104.81 (13.56)   104.19 (11.00)   104.40 (11.43)   359
                FIQ   98.38 (15.54)      99.11 (15.26)    100.79 (13.70)     366   104.54 (12.82)   103.89 (10.50)   103.77 (10.18)   359
                      **AA**             **AT**           **TT**                   **AA**           **AT**           **TT**           
                      *0.44*             *0.47*           *0.09*                   *0.42*           *0.45*           *0.13*           
  rs1364409     PIQ   95.30 (19.27)      93.93 (18.99)    97.16 (19.92)      361   105.16 (12.83)   104.52 (11.30)   104.31 (10.57)   350
  (136262573)   VIQ   102.30 (13.91)     102.93 (12.01)   105.86 (12.48)     362   104.61 (12.56)   104.45 (11.76)   104.02 (10.85)   350
                FIQ   98.72 (16.00)      98.47 (14.31)    102.82 (15.57)     361   104.56 (12.20)   104.03 (11.03)   103.49 (9.34)    350
                      **CC**             **CT**           **TT**                   **CC**           **CT**           **TT**           
                      *0.44*             *0.46*           *0.10*                   *0.42*           *0.46*           *0.13*           
  rs7782965     PIQ   95.14 (19.46)      93.97 (19.25)    96.66 (19.06)      345   104.35 (11.87)   104.81 (11.51)   104.50 (10.67)   345
  (136274673)   VIQ   101.96 (14.03)     102.56 (11.75)   105.31 (13.17)     346   104.04 (12.35)   104.47 (11.61)   103.66 (10.93)   345
                FIQ   98.43 (16.17)      98.28 (14.35)    102.18 (15.52)     345   103.85 (11.53)   104.16 (11.08)   103.34 (9.35)    345
                      **AA**             **AG**           **GG**                   **AA**           **AG**           **GG**           
                      *0.41*             *0.48*           *0.11*                   *0,39*           *0,46*           *0,15*           
  rs1378646     PIQ   95.87 (18.83)      93.78 (18.93)    96.80 (19.62)      365   104.52 (13.00)   104.92 (11.160   104.61 (10.59)   363
  (136214872)   VIQ   102.21 (14.06)     103.03 (11.85)   104.41 (12.74)     366   104.06 (13.22)   105.03 (11.61)   103.87 (11.01)   363
                FIQ   98.97 (15.80)      98.48 (14.24)    101.62 (15.39)     365   103.98 (12.73)   104.55 (10.72)   103.50 (9.51)    363
                      **AA**             **AG**           **GG**                   **AA**           **AG**           **GG**           
                      *0.44*             *0.44*           *0.12*                   *0.42*           *0.47*           *0.11*           
  rs2061174     PIQ   95.56 (18.61)      93.58 (20.13)    96.66 (18.12)      363   103.33 (12.81)   105.34 (11.33)   105.11 (9.40)    389
  (136311940)   VIQ   101.55 (13.93)     102.89 (12.32)   106.34 (11.77)     364   103.60 (13.62)   105.36 (11.03)   102.64 (10.43)   389
                FIQ   98.40 (15.60)      98.40 (15.37)    102.14 (14.06)     363   103.16 (12.82)   104.93 (10.23)   102.88 (8.97)    389
                      **TT**             **CT**           **CC**                   **TT**           **CT**           **CC**           
                      *0.48*             *0.42*           *0.10*                   *0.59*           *0.34*           *0.07*           
  rs17411561    PIQ   87.19 (19.37)      95.95 (18.21)    94.89 (19.64)      345   107.15 (11.31)   103.48 (11.47)   105.02 (11.83)   307
  (136332728)   VIQ   99.53 (12.25)      103.45 (12.94)   103.71 (12.72)     346   108.09 (10.22)   103.21 (10.44)   104.54 (12.44)   307
                FIQ   92.72 (15.08)      99.94 (14.63)    99.54 (15.76)      345   107.24 (10.13)   102.78 (10.31)   104.39 (11.61)   307
                      **AA**             **AG**           **GG**                   **AA**           **AG**           **GG**           
                      *0.29*             *0.50*           *0.21*                   *0,25*           *0,49*           *0,26*           
  rs324640      PIQ   94.72 (19.94)      94.04 (19.09)    96.61 (18.68)      363   102.21 (12.83)   105.64 (11.55)   104.37 (11.03)   386
  (136339536)   VIQ   101.70 (13.90)     102.77 (12.79)   103.88 (12.38      364   102.81 (13.92)   105.69 (11.70)   103.35 (11.26)   386
                FIQ   97.88 (16.29)      98.53 (14.79)    100.83 (15.15)     363   102.08 (12.61)   105.36 (11.12)   103.17 (10.02)   386
                      **AA**             **AT**           **TT**                   **AA**           **AT**           **TT**           
                      *0.30*             *0.48*           *0.21*                   *0.26*           *0.48*           *0.26*           
  rs324650      PIQ   93.59 (19.42)      94.45 (19.20)    96.82 (18.40)      363   102.59 (12.51)   105.50 (11.83)   104.19 (11.11)   369
  (136344201)   VIQ   101.43 (13.98)     102.73 (12.76)   104.36 (11.92)     364   103.37 (13.52)   105.61 (11.69)   102.83 (11.48)   369
                FIQ   97.14 (15.99)      98.73 (14.95)    101.26 (14.60)     363   102.54 (12.28)   105.25 (11.38)   102.83 (10.21)   369

###### 

Population and family-based QTDT results for *young*cohort for the most significant variants among *CHRM2*gene

                       Population-based   Family-based                                                   
  ------------- ------ ------------------ -------------- ------- ---------- ----- ---------- ----------- --------------
  rs2350780     PIQ    366                0.74           0.390   1.34 (G)   95    1.81       0.179       3.63 (A)
  (136243509)   VIQ    366                1.62           0.203   1.42 (G)   95    2.11       0.147       2.47 (A)
                FSIQ   366                1.82           0.177   1.68 (G)   95    2.94       0.086       3.48 (A)
  rs1364409     PIQ    362                0.13           0.718   0.57 (T)   96    0.67       0.413       2.33 (A)
  (136262573)   VIQ    362                1.46           0.227   1.42 (T)   96    1.02       0.313       1.84 (A)
                FSIQ   362                0.92           0.337   1.37 (T)   96    1.14       0.286       2.23 (A)
  rs7782965     PIQ    346                0.17           0.680   0.77 (T)   85    0.18       0.671       2.00 (C)
  (136274673)   VIQ    346                1.57           0.210   1.42 (T)   85    0.43       0.512       1.74 (C)
                FSIQ   346                1.03           0.310   1.37 (T)   85    0.94       0.332       2.05 (C)
  rs1378646     PIQ    366                0.00           1.000   0.00 (G)   98    0.20       0.655       1.26 (A)
  (136214872)   VIQ    366                0.88           0.348   1.03 (G)   98    0.66       0.417       1.39 (A)
                FSIQ   366                0.32           0.572   0.76 (G)   98    0.59       0.442       1.55 (A)
  rs2061174     PIQ    363                0.01           0.920   0.19 (G)   111   0.41       0.522       1.69 (A)
  (136311940)   VIQ    363                3.25           0.071   1.94 (G)   111   1.10       0.294       1.68 (A)
                FSIQ   363                1.10           0.294   1.37 (G)   111   0.98       0.322       1.91 (A)
  rs17411561    PIQ    345                1.20           0.273   1.91 (C)   85    0.23       0.632       1.47 (C)
  (136332728)   VIQ    345                2.51           0.113   1.81 (C)   85    5.09       0.024       4.35 (C)
                FSIQ   345                2.79           0.095   2.29 (C)   85    2.59       0.108       3.61 (C)
  rs324640      PIQ    363                0.62           0.620   1.34 (G)   105   1.51       0.219       3.45 (A)
  (136339536)   VIQ    363                2.83\*         0.093   1.94 (G)   105   **6.67**   **0.010**   **4.59 (A)**
                FSIQ   363                2.39           0.122   1.98 (G)   105   4.57       0.033       4.42 (A)
  rs324650      PIQ    363                1.65           0.199   2.10 (T)   100   2.51       0.113       4.40 (T)
  (136344201)   VIQ    363                4.56\*         0.033   1.42 (T)   100   **9.50**   **0.002**   **5.30 (T)**
                FSIQ   363                4.55           0.033   2.74 (T)   100   **7.14**   **0.008**   **5.35 (T)**

\*Stratification significant at *P*= 0.05

*Note*: N denotes the number of individuals informative for the within family association test, i.e. those individuals that occur in families with more than one genotype. QTDT assumes equal genotypes for MZ twins and includes non-typed MZ co-twins with IQ scores. *Abbreviation*: GE genotypic effect (increaser allele).

###### 

Population and family-based QTDT results for *adult*cohort for the most significant variants among *CHRM2*gene

                       Population-based            Family-based                                           
  ------------- ------ ------------------ -------- -------------- ---------- ----- ---------- ----------- --------------
  rs2350780     PIQ    359                0.26     0.610          0.47 (A)   95    3.62       0.057       3.31 (A)
  (136243509)   VIQ    359                0.01     0.920          0.12 (A)   95    0.62       0.431       1.26 (A)
                FSIQ   359                0.05     0.823          0.22 (A)   95    1.98       0.159       2.22 (A)
  rs1364409     PIQ    350                0.15     0.699          0.35 (A)   92    4.90       0.027       3.13 (A)
  (136262573)   VIQ    350                0.05     0.823          0.24 (A)   92    0.02       0.888       1.05 (A)
                FSIQ   350                0.05     0.823          0.22 (A)   92    1.25       0.264       0.72 (A)
  rs7782965     PIQ    345                0.94     0.332          0.93 (C)   91    5.29       0.021       3.36 (C)
  (136274673)   VIQ    345                0.24     0.624          0.49 (C)   91    0.33       0.566       0.16 (C)
                FSIQ   345                0.43     0.512          0.67 (C)   91    2.08       0.149       1.60 (C)
  rs1378646     PIQ    363                1.08\*   0.303          1.05 (A)   90    **6.48**   **0.011**   **3.77 (A)**
  (136214872)   VIQ    363                0.61     0.435          0.73 (A)   90    1.27       0.26        1.10 (A)
                FSIQ   363                0.76     0.383          0.78 (A)   90    3.65       0.056       2.36 (A)
  rs2061174     PIQ    389                4.64\*   0.031          2.10 (A)   101   **9.14**   **0.003**   **6.89 (A)**
  (136311940)   VIQ    389                0.06     0.806          0.24 (A)   101   0.01       0.920       1.78 (A)
                FSIQ   389                0.97     0.325          0.89 (A)   101   1.82       0.177       3.76 (A)
  rs17411561    PIQ    306                0.15     0.699          0.47 (T)   79    1.28       0.589       0.69 (C)
  (136332728)   VIQ    306                0.42     0.517          0.24 (T)   79    0.15       0.699       0.44 (T)
                FSIQ   306                0.02     0.888          0.11 (T)   79    0.60       0.439       0.08 (C)
  rs324640      PIQ    386                2.37     0.124          1.40 (A)   123   2.36       0.126       3.05 (A)
  (136339536)   VIQ    386                0.02     0.888          0.12 (A)   123   0.21       0.647       1.57 (A)
                FSIQ   386                0.54     0.462          0.67 (A)   123   1.04       0.308       2.22 (A)
  rs324650      PIQ    369                2.09     0.148          1.28 (A)   117   2.69       0.101       1.69 (T)
  (136344201)   VIQ    369                0.15     0.699          0.36 (A)   117   0.00       1.000       0.78 (T)
                FSIQ   369                0.13     0.718          0.33 (T)   117   0.58       0.446       0.77 (T)

\*Stratification significant at *P*= 0.05

*Note*: N denotes the number of individuals informative for the within family association test, i.e. those individuals that occur in families with more than one genotype. QTDT assumes equal genotypes for MZ twins and includes non-typed MZ co-twins with IQ scores. *Abbreviation*: GE genotypic effect (increaser allele).

CHRM2 transcripts expression at brain level and correlations with CHRM2 tag-SNPs
--------------------------------------------------------------------------------

Previous studies have shown that of the six known isoforms of *CHRM2*only C and D are expressed in the brain \[[@B17],[@B18]\]. In contrast to this, we observed all six CHRM2 transcripts isoforms in brain material(data not shown).

After normalizing raw gene expression data to expression level of the housekeeping genes, no correlation between gene expression and *CHRM2*gene genotypes for SNPs rs2061174, rs324640 or rs324650 was observed (data not shown).

Discussion
==========

Converging evidence from previous studies \[[@B7]-[@B9]\] has pointed to a role of the *CHRM2*gene in intelligence. None of these studies, however, have identified the functional polymorphism explaining its role at a molecular level. The present study aimed to zoom in on the functional variants, by fine-mapping the most significant areas within this gene and also investigating differential brain expression as a function of different genotypes on the SNPs most strongly related to intelligence.

A total of 42 SNPs within the *CHRM2*gene were genotyped in a *young*and *adult*cohort. Association analysis was conducted separately in both age cohorts to detect possible age dependent gene effects. Associations were found in different regions of the gene for each age cohort. Our current analyses showed that the same SNPs that were associated previously with intelligence, were again most significant, whereas a new SNP (rs2350780) showed a trend towards significance. Because of the dense coverage of SNPs used in this study, this confirms the importance of intron 4 and intron 5 regions, but rules out association with SNPs located elsewhere in the gene.

Four new SNPs in the intron 3 region, (rs2350780, rs1364409, rs7782965, and 1378646) showed association with PIQ in the *adult*cohort. These SNPs are in high LD (r^2^between 0.58 -- 0.72) between the most significant SNPs. SNP rs2350780 and rs2061174 were also found to be associated with intelligence by Dick and co-workers \[[@B9]\]. These intronic SNPs are located 68 kb apart in introns 3 and 4, respectively. In our cohort, LD between these two variants is 0.58.

We found the most significant associations with PIQ in adults (rs2061174, χ^2^= 9.14; *P*= *0.003*) and with VIQ in children (rs323650, χ^2^= 9.50; *P*= *0.002*). Because only part of the variance in PIQ and VIQ is shared, and these results might reflect brain maturation processes and age-related genetic effects. Alternatively, the results could point to, and potentially explain, the genetic overlap between PIQ and VIQ, in which common genetic variants do not only interact modulating hippocampal neurotransmitter activity, but also and even more interesting from the epigenetic point of view, they might modulate priming and dendritic outgrowth underlying synaptic plasticity during embryogenesis \[[@B39]\] and at a post-natal stage \[[@B40]\], reflecting phenotypic variation at different IQ domains across the lifespan.

From a developmental perspective, brain maturation can be considered the most complex and dynamic lifelong process taking place in humans. Neuronal plasticity patterns (e.g. dendritic \"pruning\", synapse elimination, myelination) have been shown to vary significantly across life and among diverse brain structures (for a review see Toga et al., 2006 \[[@B41]\]). Variation in cognitive phenotypes may be the result of diverse allele-dependent effects that, although small in effect size, may contribute to cognitive phenotypes outcomes across life.

*In situ*hybridization experiments on mammals (e.g. mice) \[[@B42]\] have been of great utility to aid specific localization and interpretation of gene expression patterns. However, the localization of CHRM2 receptors transcripts has been conducted using probe sequences that did not distinguish between alternatively spliced transcripts. Our gene expression analyses showed that, in contrast to previously reported findings \[[@B17],[@B18]\], all six currently known transcripts (isoforms A till F) of the *CHRM2*gene were present in brain tissue.

Our genotype-dependent CHRM2 expression, did not reveal functional significance of any of the SNPs that were significantly related to intelligence. However, one should keep in mind that at this point we were only able to study material from superior and inferior parietal lobe and further studies on other brain regions might give different results. Furthermore it would be of interest to examine allele-specific effects on CHRM2 transcripts expression in much more detail, for example in relation to transcripts specific halve-life and their relation to LTP and memory.

Although brain expression analysis did not reveal differential expression of CHRM2 transcripts, our study further zooms in on the *CHRM2*gene, clearly confirming two regions of most importance to intelligence within introns 4 and 5. These regions are poorly conserved regions among relatively distant species, although they are conserved among primate species. Interestingly, the variant associated in the *young*cohort (rs324650) is located within a SINE repeat (MIRb). SINE repeats belongs to a wide family of transposable elements, which constitute the largest class of interspersed repeats that are found in our genome (12%) together with long interspersed repeats (LINE) an long terminal repeats (LTRs) \[[@B43]\]. SINE repeats transpose through a RNA intermediate (reverse transcription process). All eukaryotic genomes contain mobile elements (retrosposable elements), although the proportion and activity of the classes of elements varies widely between genomes \[[@B44]\]. The *CHRM2*gene, like its G-protein receptor counterparts, shares the interestingly feature -- at least form a functional perspective -- of being an *intronless*protein \[[@B45]\], which is also observed among dopamine receptors \[[@B46]\], widely studied in relation to attention deficits.

Recent research has revealed a potential functionality of retroposons in a gene-regulatory context \[[@B38],[@B47]-[@B50]\]. It has been postulated that retroposon insertion processes may favour the generation of *intronless*proteins (for a review see Flavell 1995 and Brosius 2003 \[[@B51],[@B52]\]). If this hypothesis holds, the resulting *intronless*proteins are expected to contain exons among their 5\'UTR region. Not surprisingly, among G-proteins with intronless open reading frames (ORFs), about 18% have been reported to contain untranslated exons on their 5\'UTR \[[@B46],[@B53]\].

The majority of mammalian GPCRs are related to central nervous system activity, which often requires high and differential expression of many genes \[[@B53],[@B54]\].

Conclusion
==========

Multiple promoters and transcripts have been reported for the *CHRM2*gene suggesting that the associated regions we identified harbour functional elements involved in regulation of transcription and/or alternative splicing \[[@B17]-[@B19]\]. Further investigation involving functional assays and non-coding polymorphisms may aid the search and subsequent identification of regulatory variants underlying normal cognitive variation.
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